If we recall what was on the table with CETA, there were three requests: patent term restoration, data protection, and right of appeal. In the agreement in principle it looks as if it was two out the three, which is progress, and I'm very pleased about it. But if with one of the three isn't really progress—and again, the devil is in the details, as Darren has talked about—that's not going to achieve what we set out to do, to try to get the environment to attract more investment in Canada.
To me, the balance is to win those contracts to come to Canada. There's lots of room in our health care system for generics and for innovators. But we have to create the environment to attract the investment here. I've always believed the generics should probably be supporting us more, because without our innovation they have nothing to copy. But they do have a role at the end of patent. We have to make sure that we have the environment, that we can do the research, and that it's protected. That's what we're trying for, and that's the balance I think we should be going for, to make sure there's enough in CETA to attract new dollars into Canada.